Enveric Biosciences (NASDAQ: ENVB) shares Q1 2026 investor presentation details

Rhea-AI Filing Summary

Enveric Biosciences, Inc. filed a current report to let investors know that it has prepared an updated Q1 2026 Investor Presentation. Management plans to post this presentation on the company’s website on or about January 9, 2026 and may use it in future meetings with investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and other interested parties.

The presentation is furnished as Exhibit 99.1 and is also accessible through Enveric’s investor events webpage, although website materials are not part of the report. The company specifies that the Investor Presentation is being “furnished” under Regulation FD rather than “filed,” which means it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.

false 0000890821 0000890821 2026-01-09 2026-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934

January 9, 2026

Date of Report (Date of earliest event reported)

Enveric Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38286		95-4484725
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Enveric Biosciences, Inc.

245 First Street, Riverview II, 18th Floor

Cambridge, MA, 02142

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (617) 444-8400

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the ExchangeAct (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the ExchangeAct (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the ExchangeAct (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of theAct:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		ENVB		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐

Item 7.01 Regulation FD Disclosure.

Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about January 9, 2026. From time to time thereafter, the Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others with an interest in the Company and its business.

A copy of the Investor Presentation is furnished as Exhibit 99.1 to this report and incorporated here by reference. A copy of the Investor Presentation is also available via the Company’s website at https://www.enveric.com/investors/events/. Materials on the Company’s website are not part of or incorporated by reference into this report.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the ExchangeAct, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Investor Presentation Q1 2026 (furnished pursuant to Item 7.01)
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 9, 2026	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph Tucker, Ph.D.
		Chief Executive Officer

FAQ

What did Enveric Biosciences (ENVB) disclose in this 8-K filing?

Enveric Biosciences disclosed that it has prepared a new Investor Presentation for Q1 2026, which management plans to post on its website and use in meetings with investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and other interested parties.

Where can investors access Enveric Biosciences' Q1 2026 Investor Presentation?

The Q1 2026 Investor Presentation is furnished as Exhibit 99.1 to the report and is also available on Enveric Biosciences’ website at https://www.enveric.com/investors/events/, although website materials are not incorporated by reference into the report.

Is the Enveric Biosciences (ENVB) Investor Presentation considered filed with the SEC?

No. The company states that the information in the report, including Exhibit 99.1, is being furnished under Regulation FD and is not deemed to be filed for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference into another filing.

What is the purpose of Enveric Biosciences’ Regulation FD disclosure in this 8-K?

The purpose is to provide broad, non-selective disclosure by making the Q1 2026 Investor Presentation available to the market, while clarifying that it may be used in various communications with investors and other stakeholders.

Who signed the Enveric Biosciences (ENVB) 8-K related to the Investor Presentation?

The report was signed on behalf of Enveric Biosciences, Inc. by Joseph Tucker, Ph.D., who is identified as the company’s Chief Executive Officer.